TEGA Therapeutics

United States
San Diego, California, United States, 92093

Company profile

TEGA Therapeutics company profile

TEGA was founded to exploit glycoscience-related technologies for the treatment of life-threatening diseases. Glycans, or complex carbohydrates, play important roles in many physiological and pathophysiological processes, but their value as pharmaceutical targets remains underexploited by industry. TEGA specializes in the science of glycans. The TEGA pipeline includes two major programs: glycoside-enhanced lysosomal delivery of proteins and recombinant production of heparan sulfate and heparin. They aim to improve quality of life for patients by enabling delivery of lifesaving treatments for unmet medical needs. Their work is motivated by a commitment to innovation and helping patients. They combine their powerful insights and rigorous scientific methods to help pharmaceutical companies overcome the obstacle of the blood-brain barrier.

Business identity

Contact email
[email protected]
Phone number
619-838-8579
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0-$1M
Founded
2014-01-01, Year

Headquarters

Postal code
92093
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding rounds
4
Last funding
Grant / $999,948 / 2020-12-16
Investors
2
Lead investors
1
Founders
1
Articles
4

Founders and investors

Founders

Timothy Scott

Lead investors

National Science Foundation

Investors

National Science FoundationTCA Venture Group